Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2006 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00317668
First received: April 23, 2006
Last updated: April 29, 2007
Last verified: April 2006
  Purpose

The investigators will check the serum of epilepsy patients for antibodies against glutamate receptors and double stranded DNA. They will characterise the patients (by the kind of epilepsy, autoimmune disease comorbidity, and cognitive profile).


Condition
Epilepsy

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 250
Study Start Date: November 2006
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 120 epilepsy patients from the epilepsy clinic and Emergency Room (ER)
  • Controls: 100 patients with other neurological diseases and no epilepsy; and 30 healthy volunteers.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00317668

Contacts
Contact: Dana Ekstein, MD dekstein@md.huji.ac.il

Locations
Israel
Hadassah Ein-Kerem Medical Center Recruiting
Jerusalem, Israel
Principal Investigator: Dana Ekstein, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Dana Ekstein, MD Hadassah Medical Organization
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00317668     History of Changes
Other Study ID Numbers: autoimmunepi-HMO-CTIL
Study First Received: April 23, 2006
Last Updated: April 29, 2007
Health Authority: Israel: Ethics Commission

Additional relevant MeSH terms:
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on October 20, 2014